LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...
In 2022, Dexcom began rolling out in Europe the Dexcom One system, a straightforward continuous glucose monitoring setup that stripped away some of the bells and whistles of its flagship G-series CGMs ...
The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...
The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results